

Dup

Hässle 4

5. seiten

1/52



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 074 341

A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 82850166.8

(51) Int. Cl.³: C 07 D 401/12

A 61 K 31/415, A 61 K 31/44

(22) Date of filing: 11.08.82

(30) Priority: 13.08.81 SE 8104811

(43) Date of publication of application:
16.03.83 Bulletin 83/11

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: Aktiebolaget Hässle
Kärragatan 5
S-431 83 Mölndal(SE)

(72) Inventor: Carlsson, Enar Ingemar
Ingegårdsvägen 2C
S-421 68 Frölunda(SE)

(72) Inventor: Junggren, Ulf Krister
Dammvägen 7
S-43500 Mölnlycke(SE)


(72) Inventor: Larsson, Hakan Sigurd
Hägalundsvägen 4
S-430 65 Rävlanda(SE)

(72) Inventor: von Wittken Sundell, Gunhild Wika
Solliden 2
S-436 00 Askim(SE)

(74) Representative: Wurm, Bengt Runio et al,
Patent and Trade Mark Department Ab Astra
S-151 85 Södertälje(SE)


(54) Novel pharmaceutical compositions.

(57) A pharmaceutical preparation containing as active ingredient a compound of the formula



or a therapeutically acceptable salt thereof in which formula
R¹ and R² are the same or different and each selected
from the group consisting of H, CF₃, NO₂, -COOCH₃,
-COOC₂H₅, alkyl containing 1-7 carbon atoms, halogen,
alkoxy, containing 1-5 carbon atoms, and alkanoyl contain-
ing 1-4 carbon atoms.

R is selected from the group consisting of H, alkanoyl



./...

EP 0 074 341 A1

Novel Pharmaceutical CompositionsDESCRIPTION5 Field of the invention.

The object of the present invention is to provide compounds which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the treatment of peptic ulcer.



The present invention relates to the use of a group of benzimidazole derivatives, or therapeutically acceptable salts thereof, for inhibiting gastric acid secretion in mammals and man. In a more general sense, the invention relates to the use of the compounds for treatment of gastrointestinal inflammatory diseases in mammals and man, including i.e. gastric and duodenal ulcer. Furthermore it relates to the use of these compounds for treatment of other gastrointestinal disorders, where a gastric anti-secretory effect is desirable i.e. in patients with gastrinomas and in patients with acute upper gastrointestinal bleeding. The invention also relates to pharmaceutical compositions containing at least one member of the said group of benzimidazole derivatives, or a therapeutically acceptable salt thereof, as active ingredient. In a further aspect, the invention relates to new compounds, and therapeutically acceptable salts thereof, within the said group of benzimidazole derivatives, and to processes for preparation of such new compounds.

Prior art

Benzimidazole derivatives intended for inhibiting gastric acid secretion are disclosed in the British patent specifications 1 500 043 and 1 525 958, in the US patent 4 182 766 and in the European patent specification No. 0 005 129.

The invention

It has been found that the compounds of the formula



I

and therapeutically acceptable salts thereof in which formula

R^1 and R^2 are the same or different and each selected from the group consisting of H, CF_3 , NO_2 , $-COOCH_3$, $-COOC_2H_5$, alkyl containing 1-7 carbon atoms, halogen, alkoxy containing 1-5 carbon atoms, and alkanoyl containing 1-4 carbon atoms;

R is selected from the group consisting of H, alkanoyl containing 1-4 carbon atoms, and carboalkoxy containing 2-6 carbon atoms;

and R^3 , R^4 and R^5 , which are the same or different, are each selected from the group consisting of H, CH_3 , C_2H_5 , OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$, provided that

a) at least one of R^3 , R^4 and R^5 is selected from the group consisting of CH_3 , C_2H_5 , OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$, and

b) when two of R^3 , R^4 and R^5 are H, then the remaining radical R^3 , R^4 or R^5 is selected from the group consisting of OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$;



are effective as inhibitors of gastric acid secretion in mammals and man. The compounds of the formula I, and therapeutically acceptable salts thereof, are stable in gastric juice, which is of importance at oral administration.

5

Illustrative examples of the radicals in the formula I are:

10 Alkyl groups R^1 and R^2 : methyl, ethyl, n-propyl, i-propyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, n-hexyl, n-heptyl. It is preferred that alkyl groups R^1 and R^2 contains 1, 2, 3 or 4 carbon atoms. The preferred alkyl group is methyl.

15 Halogen R^1 and R^2 : chloro, bromo, fluoro, iodo. The preferred halogen groups are chloro and bromo.

20 Alkoxy groups R^1 and R^2 : methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, sec.-butoxy, isobutoxy, tert.-butoxy, n-pentoxy. It is preferred that alkoxy groups R^1 and R^2 contain 1, 2 or 3 carbon atoms. The preferred alkoxy group is methoxy.

25 Alkanoyl groups R , R^1 and R^2 : $HCO-$, CH_3CO- , CH_3CH_2CO- , $CH_3CH_2CH_2CO-$, $HC(CH_3)_2CO-$. The preferred alkanoyl group R^1 and R^2 is CH_3CO . The preferred alkanoyl group R is CH_3CO .

30 Carboalkoxy groups R : $CH_3OC(=O)-$, $CH_3CH_2OC(=O)-$, $CH_3CH_2CH_2OC(=O)-$, $HC(CH_3)_2OC(=O)-$, $CH_3(CH_2)_3OC(=O)-$, $CH_3(CH_2)_4OC(=O)-$. It is preferred that

35 carboalkoxy groups R contains 2 or 3 carbon atoms. Thus, the groups CH_3OCO- and CH_3CH_2OCO- are preferred.




The preferred meaning of the radical R is H.

Preferred combinations of the radicals in the formula I, subject to the two provisos a) and b) given above, are given in Table 1 below.

Table 1

Preferred combinations of R^1 , R^2 , R, R^3 , R^4 and R^5 .

R^1 and R^2 , the same or different if not indicated otherwise	R	R^3 , R^4 and R^5 , the same or different if not indicated otherwise
H, COOCH ₃ , COOC ₂ H ₅ , alkyl, halogen, alkoxy, alkanoyl	H	H, CH ₃ , C ₂ H ₅ , OCH ₃ , OC ₂ H ₅ , OCH ₂ CH ₂ OCH ₃ , OCH ₂ CH ₂ OCH ₂ CH ₃
H, COOCH ₃ , CH ₃ , Cl, Br, OCH ₃ , CH ₃ CO	H	H, CH ₃ , C ₂ H ₅ , OCH ₃ , OCH ₂ CH ₂ OCH ₃
H, COOCH ₃ , CH ₃ , OCH ₃ , CH ₃ CO	H	CH ₃ , OCH ₃
H, COOCH ₃ , alkyl, alkoxy, alkanoyl	H	H, CH ₃ , OCH ₃ , OC ₂ H ₅
H, COOCH ₃ , COOC ₂ H ₅ , alkyl, halogen, alkoxy, alkanoyl	H	R^3 : CH ₃ R^4 : OCH ₃ R^5 : CH ₃
H, COOCH ₃ , COOC ₂ H ₅ , alkyl, alkoxy, alkanoyl	H	R^3 : H R^4 : OCH ₃ R^5 : CH ₃
NO ₂ , CF ₃	H	R^3 : CH ₃ R^4 : OCH ₃ R^5 : CH ₃



R^1 and R^2 , the same or different if not indicated otherwise	R	R^3 , R^4 and R^5 , the same or different if not indicated otherwise
10 H, COOCH ₃ , COOC ₂ H ₅ , alkyl, alkoxy, alkanoyl	H	R^3 : CH ₃ R^4 : OCH ₃ R^5 : H
15 H, COOCH ₃ , COOC ₂ H ₅ , alkyl, alkoxy, alkanoyl	H	R^3 : H R^4 : OCH ₃ R^5 : H
H, COOCH ₃ , COOC ₂ H ₅ , alkyl, alkoxy, alkanoyl	H	R^3 : CH ₃ R^4 : H R^5 : CH ₃
20 H, COOCH ₃ , COOC ₂ H ₅ , alkyl, alkoxy, alkanoyl	H	R^3 : H R^4 : OCH ₃ , OC ₂ H ₅ , OCH ₂ CH ₂ OCH ₃ , OCH ₂ CH ₂ OCH ₂ CH ₃ R^5 : H
5 H, COOCH ₃ , COOC ₂ H ₅ , alkyl, alkoxy, alkanoyl	H	R^3 : CH ₃ R^4 : CH ₃ R^5 : CH ₃

30

The radicals R^1 and R^2 can be bound to the benzimidazole nucleus in any of the positions 4, 5, 6 and 7 as depicted in formula I. It is preferred that R^1 and R^2 are in position 5 and/or 6.

35

Preferred individual compounds among those included in the formula I are given in the following Table 2:



Table 2

Preferred individual compounds

5	R ¹	R ²	R	R ³	4 ⁴	R ⁵
	5-OCH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-COOCH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-COOCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃
10	5-COCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃
	5-COCH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-CH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-COCH ₃	6-CH ₃	H	H	CH ₃	CH ₃
	5-OCH ₃	H	H	CH ₃	CH ₃	CH ₃
15	5-COCH ₃	6-CH ₃	H	H	OCH ₃	H
	5-COOCH ₃	6-CH ₃	H	CH ₃	OCH ₃	H
	5-COCH ₃	6-CH ₃	H	CH ₃	CH ₃	CH ₃
	5--COOCH ₃	6-CH ₃	H	H	OCH ₃	H

20

Further preferred individual compounds are those exemplified in the examples given elsewhere in this specification.

25 In the prior art cited above, no medicinal use is disclosed for the compounds of the formula I. Thus, the present invention comprises pharmaceutical compositions containing a compound of the formula I or a therapeutically acceptable salt thereof as active ingredient, and the use of the compounds
30 of the formula I or a therapeutically acceptable salt thereof for inhibiting gastric acid secretion in mammals and man.

The compounds of the formula I wherein R¹ and R² are as defined above except CF₃ and NO₂, R is H and R³, R⁴ and
35 R⁵ are H, CH₃, OCH₃, OC₂H₅, OCH₂CH₂OCH₃ or OCH₂CH₂OCH₂CH₃ are generically disclosed as chemical intermediates in the European patent No. 0 005 129. The specific compounds disclosed in the following Table 3 are disclosed in the said European patent No. 0 005 129.



Table 3

Compounds disclosed in European patent no. 0 005 129.

5	R	R ¹	R ²	R ³	R ⁴	R ⁵	Remark
	H	5-COCH ₃	6-CH ₃	H	CH ₃	CH ₃	base
	H	4-CH ₃	6-CH ₃	CH ₃	H	CH ₃	hydrochloride
10	H	5-COCH ₃	6-CH ₃	CH ₃	CH ₃	CH ₃	base

The present invention, in so far as it concerns compounds of the formula I by themselves, their pharmaceutically acceptable salts, and processes for their preparations, relates to


- i) the compounds of the formula I wherein R³, R⁴ or R⁵ is C₂H₅
- ii) the compounds of the formula I wherein R is alkanoyl or carboalkoxy
- iii) the compounds of the formula I wherein R is H except the compounds wherein R, R¹, R², R³, R⁴ and R⁵ are combined as follows:

R ¹	R ²	R	R ³	R ⁴	R ⁵
5-COCH ₃	6-CH ₃	H	H	CH ₃	CH ₃
4-CH ₃	6-CH ₃	H	CH ₃	H	CH ₃
5-COCH ₃	6-CH ₃	H	CH ₃	CH ₃	CH ₃

- iv) the compounds of the formula I wherein R¹ and/or R² are CF₃ or NO₂.


The preferred compounds within the groups i), ii), iii) and iv) will comprise the same compounds that are indicated as preferred in Table 1 and Table 2 above, subject to the

proviso that the specific compounds listed in Table 3 are excluded.




The compounds of the formula I can be prepared by known methods such as

A. reacting a compound of the formula




15 with a compound of the formula



in which formulas R, R¹, R², R³, R⁴ and R⁵ are as defined previously and wherein one of Z¹ and Z² is SH and the other is a leaving group.

25 Examples of leaving groups Z¹ and Z² in the compounds II and III are halogens, preferably chlorine, bromine or iodine, acyl radicals, for example, residues of strong organic sulfonic acids, for instance, of an arylsulfonic acid, for example, tosyloxy, or an alkylsulfonic acid, for example, mesyloxy; alkylmercapto groups, for example, methylmercapto; alkylsulfinyl groups, for example, methylsulfinyl and the like.

35 Thus, Z¹ or Z² when designating leaving groups may be a reactive esterified hydroxy group.



The reaction of a compound of formula II above with a compound of formula III is conveniently carried out in the presence of a suitable solvent that is inert under the reaction conditions utilized as described hereinafter. The reaction may further be carried out in the presence of a suitable base. Suitable bases include, for example, inorganic bases such as sodium or potassium hydroxide, sodium or potassium hydride and the like, organic bases such as tertiary amines, for example, triethylamine and the like.

10


Suitable solvents for the above described reaction include, for example, alcohols, preferably lower alkanols such as, methanol and ethanol; mixtures of such alcohols with water, ethers, such as, tetrahydrofuran; halogenated hydrocarbons, such as, methylene chloride and chloroform, and the like.

15

The reaction of the compounds of formulas II and III may be carried out at a temperature between the ambient temperature and the boiling temperature of the reaction mixture. It is preferred to carry out the reaction, however, at a temperature at or close to the boiling point of the reaction mixture for the preparation of a compound of the formula I wherein R is H;

20


25 B. reacting a compound of the formula



IV

30

wherein R^1 and R^2 have the same meaning as given above with a compound of the formula




35

V




wherein R^3 , R^4 and R^5 have the same meaning as given above, to the formation of a compound of the formula I wherein R is H;

5 C. reacting a compound of the formula



VI

wherein R, R^1 and R^2 have the meaning given above and M is K, Na or Li, with a compound of formula




VII

wherein R^3 , R^4 and R^5 have the meaning given above and Z^3 is a reactive esterified hydroxy group, to the formation of a compound of the formula I.

25 The reactive esterified hydroxy group Z^3 may, as in the case of Z^1 and Z^2 , be a hydroxy group esterified with a strong, inorganic or organic acid, preferably a hydrohalogen acid, such as hydrochloric acid, hydrobromic acid, or hydroiodic acid, or esterified with sulfuric acid or
30 with a strong organic sulfonic acid such as a strong aromatic acid, e.g. benzenesulfonic acid, 4-bromobenzenesulfonic acid or 4-toluenesulfonic acid.




D. reduction of a compound of the formula



10 to the formation of a compound of the formula I:

E. for the preparation of a compound of the formula I wherein the radicals R^1 and/or R^2 is COOCH_3 or COOC_2H_5 , reacting a compound of the formula


15



20

wherein R , R^3 , R^4 or R^5 are as defined above and wherein Y^1 is $-\text{COOH}$, or a functionally equivalent derivative thereof, and Y^2 is $-\text{COOH}$, or a functionally equivalent derivative thereof, or R^1 , with


25



X

30

or



XI

35

or a functionally equivalent derivative thereof, to the formation of a compound of the formula I wherein R^1 and/or R^2 is CH_3COO or $\text{CH}_3\text{CH}_2\text{COO}$.




This reaction is an ordinary esterification which is carried out in customary manner.

Functionally equivalent derivatives of the hydroxy group in the compounds X and XI are for example halogen such as Cl or Br, or $-N_2$.

Functionally equivalent derivatives of the carboxyl group Y^1 and Y^2 are for example a metal carboxylate group or an activated carboxyl group, in which case the radicals Y^1 or Y^2 are for example an acid chloride, an alkyl ester, an acid anhydride or a mixed anhydride with formic esters or carboxylic acids, sulphonic or inorganic esters or derivatives obtained by a reaction between a carboxylic acid and a carbodiimide or similarly functioning compounds such as N,N^1 -carbonyldiimidazole or N-ethyl-5-phenylisoxazolium-3¹-sulphonate, the derivative of the carboxyl group Y^1 or Y^2 being a metal carboxylate group when the hydroxyl group in the compounds X or XI is replaced with halogen. A further functionally equivalent derivative of the carboxyl groups Y^1 and Y^2 is the group $-CN$, in which case a cyanide is reacted with a compound of the formula X or XI with subsequent hydrolysis to give a compound of the formula I wherein R^1 and/or R^2 is CH_3COO or CH_3CH_2COO .


F. for the preparation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$, reacting a compound of the formula



XII




wherein R , R^1 and R^2 , are as defined above and Z^3 , Z^4 and Z^5 represent either R^3 , R^4 and R^5 , respectively, or halogen such as Cl, Br, F or I, or NO_2 , whereby at least one of Z^3 , Z^4 and Z^5 represents halogen or NO_2 , with a compound of the formula



XIII


wherein R^6 is CH_3 , C_2H_5 , $CH_2CH_2OCH_3$ or $CH_2CH_2OCH_2CH_3$, and M is Na, K, or Li, to the formation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$;

G. for the preparation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$, reacting a compound of the formula




XIV

wherein R , R^1 and R^2 are as defined above, and Z^6 , Z^7 and Z^8 represent either R^3 , R^4 and R^5 , respectively, or a radical



XV

where Y is halogen, whereby at least one of Z^6 , Z^7 and Z^8 represent OCH_2CH_2Y , with a compound of the formula




XVI

wherein R^7 is CH_3 or CH_2CH_3 and M is Na, K or Li, to the formation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$.

Method F and Method G represent the known Williamson ether synthesis and is carried out in known manner.



H. for the preparation of a compound of the formula I wherein R is H, hydrolyzing a compound of the formula




XVII

wherein R^1 , R^2 , R^3 , R^4 and R^5 are as defined above and Z^9 is an alkanoyl group or a carboalkoxy group, to the formation of a compound of the formula I wherein R is H.

The radical Z^9 can be an alkanoyl group containing 1-6 carbon atoms or a carboalkoxy group containing 2-6 carbon atoms.


I. reduction of a compound of the formula



XVIII

to the formation of a compound of the formula I.

J. reduction of a compound of the formula




XIX

to the formation of a compound of the formula I.

Depending on the process conditions and the starting materials, the end product of the formula I is obtained either as the free base or as a salt. Both the free base and the salts of the end products are included within the scope of the invention. Thus, basic, neutral or mixed salts may be obtained as well as hemi-, mono-, sesqui or polyhydrates. Acid addition salts of the new compounds may in a manner known per se be transformed into free base using basic agents such as alkali or by ion exchange. The free bases obtained may also form salts with organic or inorganic acids. In the preparation of acid addition salts preferably such acids are used which form suitable therapeutically acceptable salts. Examples of such acids are hydrohalogen acids, sulfonic acid, phosphoric acid, nitric acid, and perchloric acid; aliphatic, alicyclic, aromatic or heterocyclic carboxyl or sulfonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, salicylic acid or p-aminosalicylic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, halogenbenzenesulfonic acid, toluenesulfonic acid, naphthyl-

10 The starting materials utilized in the processes A-J are known or may, if they should be new, be obtained according to processes known per se.

30 In the preparation of pharmaceutical preparations containing
a compound of the formula I in the form of dosage units for
oral administration, the active compound may be mixed with a
solid, pulverulent carrier, such as lactose, saccharose, sorbi-
tol, mannitol, a starch such as potatoe starch, corn starch, or
35 amylopectin, cellulose derivatives or gelatin, and may also
include a lubricant such as magnesium stearate, calcium




stearate or polyethyleneglycol waxes. The mixture is then pressed into tablets. If coated tablets are desired, a core prepared as described above may be coated with a concentrated sugar solution which may contain gum arabic, gelatin, talc, titanium dioxide or alternatively with a lacquer dissolved in volatile organic solvents or mixtures of solvents. To this coating various dyes may be added in order to distinguish tablets with different active compounds or with different amounts of the active compound present.

Soft gelatin capsules may be prepared which capsules contain a mixture of the active compound or compounds and vegetable oil. Hard gelatin capsules may contain granules of the active compound in combination with a solid, pulverulent carrier as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.

Dosage units for rectal administration may be prepared in the form of suppositories which contain the active substance in admixture with a neutral fatty base, or they may be prepared in the form of gelatin-rectal capsules which contain the active substance in admixture with a vegetable oil or with paraffin oil.

Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions containing from 0.2% to 20% by weight of the active ingredient, the remainder comprising for example sugar and a mixture of ethanol, water, glycerol and propylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharin and carboxymethylcellulose as a thickening agent.

Solutions for parenteral administration by injection may be prepared as sterile solution, for example in pyrogen-free



water, of a water soluble pharmaceutically acceptable salt of the active compound, preferably in a concentration from 0.5% to 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may be
5 manufactured in different dosage unit ampoules.

The dosage at which the active substance are administered may vary within a wide range and will depend on various factors such as for example the individual requirements of
10 each patient and the manner of administration. In general, oral dosages will be in the range from 100 to 400 mg/day of active substance and intravenous dosages in a range from 5 to 20 mg/day.


15 The invention is illustrated by the following examples.

Example 1. Method A. Preparation of 2-[2-(3,5-dimethyl-4-methoxy)pyridylmethylthio]-5-COCH₃-6-CH₃-benzimidazole

20 22.2 g (0.1 mole) of 3,5-dimethyl-4-methoxy-2-chloromethylpyridine hydrochloride and 20.6g (0.1 mole) of 5-COCH₃-6-CH₃-2-mercapto benzimidazole was dissolved in 250 ml methanol whereafter 4 g (0.1 mole) NaOH dissolved in 25 ml H₂O was added. The mixture was heated to reflux and
25 an additional amount of 4 g (0.1 mole) NaOH in 25 ml H₂O was added dropwise during 15 min. The mixture was thereafter refluxed during 6 hours whereafter it was cooled and diluted with 500 ml H₂O. The resulting mixture was extracted with CH₂Cl₂, dried and evaporated. The remainder was recrystallized from acetonitrile giving the title substance in the
30 form of free base. Yield: 30 g (85% of the theoretical yield). M.P.: 139°C.

0074341

19

Examples 2-50

5


The compounds identified by example numbers 2-50 in the following Table 4 were prepared using the same method of preparation as in Example 1. The compounds were obtained in the form of their free base. The compound of Example 1 is also included in the table.

10

Table 4

Identifying data for compounds of the invention


15




20

Example no	R ¹	R ²	R	R ³	R ⁴	R ⁵	M.p. °C
1	5-COCH ₃	6-CH ₃	H	H	CH ₃	CH ₃	148
2	5-COOCH ₃	6-CH ₃	H	H	CH ₃	CH ₃	125
3	5-COOCH ₃	H	H	H	CH ₃	CH ₃	136
4	5-COCH ₃	6-CH ₃	H	CH ₃	CH ₃	H	140
5	5-COOCH ₃	6-CH ₃	H	CH ₃	CH ₃	H	170 (oil)
6	4-CH ₃	6-CH ₃	H	CH ₃	H	CH ₃	206
7	5-COCH ₃	6-CH ₃	H	CH ₃	H	CH ₃	125
8	5-COCH ₃	6-CH ₃	H	CH ₃	CH ₃	CH ₃	100 (oil)
9	5-COCH ₃	6-CH ₃	H	H	OCH ₃	H	97
10	4-CH ₃	6-CH ₃	H	H	OCH ₃	H	110

cont.



Example no	R ¹	R ²	R	R ³	R ⁴	R ⁵	M.p. °C
11	5-COCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃	139
12	5-COOCH ₃	6-CH ₃	H	CH ₃	H	CH ₃	130
13	5-COOCH ₃	6-CH ₃	H	CH ₃	CH ₃	CH ₃	184
14	5-COOCH ₃	6-CH ₃	H	H	OCH ₃	H	146
15	5-COOCH ₃	6-CH ₃	H	H	OC ₂ H ₅	H	90-94
16	5-COOCH ₃	6-CH ₃	H	CH ₃	OCH ₃	H	160
17	5-COOCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃	119
18	5-COOCH ₃	6-CH ₃	H	H	OCH ₃	CH ₃	184
19	5-COOCH ₃	H	H	CH ₃	H	CH ₃	130
20	5-COOCH ₃	H	H	CH ₃	OCH ₃	CH ₃	175
21	5-COCH ₃	H	H	CH ₃	OCH ₃	CH ₃	122-124
22	5-OCH ₃	H	H	H	OCH ₃	CH ₃	168
23	5-OCH ₃	H	H	CH ₃	OCH ₃	CH ₃	110-119
24	5-CH ₃	H	H	CH ₃	OCH ₃	CH ₃	148
25	H	H	H	CH ₃	OCH ₃	CH ₃	125
26	5-Cl	H	H	CH ₃	OCH ₃	CH ₃	180
27	5-CH ₃	H	H	H	OC ₂ H ₄ OCH ₃	H	100
28	5-COOC ₂ H ₅	H	H	CH ₃	OCH ₃	CH ₃	130
29	5-OCH ₃	H	H	CH ₃	CH ₃	CH ₃	157
30	CH ₃	CH ₃	H	CH ₃	CH ₃	H	140
31	COOCH ₃	CH ₃	H	CH ₃	H	CH ₃	125
32	5-C(CH ₃) ₃	H	H	CH ₃	OCH ₃	CH ₃	
33	5-NO ₂	H	H	CH ₃	OCH ₃	CH ₃	
34	5-CH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃	
35	4-CH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃	
36	5-C ₂ H ₅	H	H	CH ₃	OCH ₃	CH ₃	
37	5-CF ₃	H	H	CH ₃	OCH ₃	CH ₃	
38	5-CH(CH ₃) ₂	H	H	CH ₃	OCH ₃	CH ₃	
39	5-Cl	6-Cl	H	CH ₃	OCH ₃	CH ₃	
40	5-OC ₂ H ₅	H	H	CH ₃	OCH ₃	CH ₃	
41	5-Br	H	H	CH ₃	OCH ₃	CH ₃	
42	5-OCH ₃	H	H	OCH ₃	H	H	cont.



Example no	R ¹	R ²	R	R ³	R ⁴	R ⁵
43	5-Cl	H	H	CH ₃	CH ₃	H
44	5-OCH ₃	H	H	CH ₃	CH ₃	H
45	5-CH ₃	7-CH ₃	H	CH ₃	CH ₃	H
46	5-OCH ₃	H	H	CH ₃	OCH ₃	H
47	5-COOCH ₃	7-CH ₃	H	CH ₃	CH ₃	H
48	5-COCH ₃	H	H	CH ₃	CH ₃	H
49	5-OCH ₃	H	H	CH ₃	OC ₂ H ₅	CH ₃
50	5-COOCH ₃	6-CH ₃	H	H	OCH ₃	C ₂ H ₅

Identifying data for the compounds according to examples 32-50 are given in the following table 5.

Table 5. NMR data for compounds of the invention

Compound according to example no.	NMR data δ
32	1.37 (s, 9H), 2.26 (s, 3H), 2.30 (s, 3H), 3.76 (s, 3H), 4.37 (s, 2H), 7.25 (k, 1H), 7.49 (d, 1H), 7.57 (d, 1H), 8.30 (s, 1H)
33	2.21 (s, 3H), 2.31 (s, 3H), 3.75 (s, 3H), 4.77 (s, 2H), 7.64 (d, 1H), 8.11 (k, 1H), 8.23 (s, 1H), 8.36 (d, 1H)

cont.




Table 5. NMR data for compounds of the invention.
continued

Compound according to example no.	NMR-data δ
34	2.23 (s,3H), 2.28 (s,3H), 2.33 (s,6H), 3.75 (s,3H), 4.33 (s,2H), 7.29 (s,2H), 8.23 (s,1H)
35	2.28 (s,3H), 2.33 (s,3H), 2.43 (s,3H), 2.58 (s,3H), 3.81 (s,3H), 4.42 (s,2H), 6.92 (s,1H), 7.29 (s,1H), 8.36 (s,1H)
36	1.25 (t,3H), 2.25 (s,3H), 2.30 (s,3H), 2.72 (k,2H), 3.76 (s,3H), 4.38 (s,2H), 7.02 (k,1H), 7.35 (d,1H), 7.45 (d,1H), 8.26 (s,1H)
37	2.31 (s,3H), 2.35 (s,3H), 3.84 (s,3H), 4.46 (s,2H), 7.51 (k,1H), 7.70 (d,1H), 7.92 (d,1H), 8.38 (s,1H)
38	1.25 (s,3H), 1.33 (s,3H), 2.27 (s,3H), 2.33 (s,3H), 3.03 (m,1H), 3.80 (s,3H), 4.51 (s,2H), 7.17 (k,1H), 7.53 (d,1H), 7.58 (d,1H), 8.36 (s,1H)
39	2.22 (s,3H), 2.31 (s,3H), 3.81 (s,3H), 4.72 (s,2H), 7.76 (s,2H), 8.23 (s,1H)
40	1.41 (t,3H), 2.30 (s,3H), 2.35 (s,3H), 3.82 (s,3H), 4.10 (k,2H), 4.39 (s,2H), 6.92 (k,1H), 7.14 (d,1H), 7.52 (d,1H), 8.40 (s,1H)

cont.

Table 5. NMR data for compounds of the invention.
continued



Compound according to example no.	NMR data δ
41	2.16 (s,3H), 2.26 (s,3H), 3.71 (s,3H), 4.68 (s,2H), 7.23 (k,1H), 7.43 (d,1H), 7.65 (d,1H), 8.18 (s,1H)
42	3.80 (s,3H), 3.83 (s,3H), 4.50 (s,2H), 6.90 (k,1H), 7.15 (d,1H), 7.24 (m,2H), 7.53 (d,1H), 8.23 (k,1H)
43	2.33 (s,3H), 2.35 (s,3H), 4.80 (s,2H), 7.19 (m,2H), 7.52 (d,1H), 7.58 (d,1H), 8.34 (d,1H)
44	2.34 (s,6H), 3.85 (s,3H), 4.51 (s,2H), 6.89 (k,1H), 7.15 (d,1H), 7.15 (d,1H), 7.53 (d,1H), 8.41 (d,1H)
45	2.16 (s,6H), 2.38 (s,3H), 2.53 (s,3H), 4.46 (s,2H), 6.86 (s,1H), 6.99 (d,1H), 7.25 (s,1H), 8.20 (d,1H)
46	2.26 (s,3H), 3.86 (s,3H), 3.91 (s,3H), 4.70 (s,2H), 6.87 (m,2H), 7.10 (d,1H), 7.48 (d,1H), 8.42 (d,1H)
47	2.36 (s,6H), 2.65 (s,3H), 3.97 (s,3H), 4.50 (s,2H), 7.17 (d,1H), 7.84 (s,1H), 8.24 (s,1H), 8.41 (d,1H),
48	2.31 (s,3H), 2.34 (s,3H), 2.64 (s,3H), 4.71 (s,2H), 7.12 (d,1H), 7.59 (d,1H), 7.91 (k,1H), 8.22 (d,1H), 8.36 (d,1H)

cont.




Table 5. NMR data for compounds of the invention.
continued

Compound according to example no.	NMR data, δ
49	1.41 (t,3H), 2.27 (s,3H), 2.31 (s,3H), 3.87 (s,3H), 3.94 (k,2H), 4.41 (s,2H), 6.89 (k,1H), 7.12 (d,1H), 7.50 (d,1H), 8.35 (s,1H)
50	1.17 (t,3H), 2.61 (k,2H), 2.69 (s,3H), 3.93 (s,6H), 4.43 (s,2H), 7.00 (s,1H), 7.45 (s,1H), 8.26 (s,1H), 8.35 (s,1H)

The starting materials in the examples 1-50 were prepared in accordance with the following:

- 1) a substituted o-phenylenediamine was reacted with potassium ethylxanthate (according to Org. Synth. Vol. 30, p. 56) to form a corresponding substituted 2-mercaptobenzimidazole;
- 2) a substituted 2-chloromethylpyridine was prepared by reacting the corresponding 2-hydroxymethylpyridine with thionylchloride;
- 3) a substituted 2-chloromethylbenzimidazole was prepared by condensing the o-phenylenediamine with chloroacetic acid.

The following examples illustrate how the compounds of the formula I can be incorporated in pharmaceutical compositions:

Example 51. Syrup

5

A syrup containing 2% (weight per volume) of active substance was prepared from the following ingredients:



2-[2-(3,5-dimethyl-4-methoxy)pyridylmethylthio]-		
10	-(5-acetyl-6-methyl)benzimidazole · HCl	2.0 g
	Saccharin	0.6 g
	Sugar	30.0 g
	Glycerin	5.0 g
	Flavouring agent	0.1 g
15	Ethanol 96%	10.0 ml
	Distilled water (sufficient to obtain a final volume of 100 ml)	

Sugar, saccharin and the acid addition salt were dissolved
20 in 60 g of warm water. After cooling, glycerin and a solution of flavouring agents dissolved in ethanol were added. To the mixture water was added to obtain a final volume of 100 ml.

25 The above given active substance may be replaced with other pharmaceutically acceptable acid addition salts.

Example 52. Tablets

30 2-[2-(3,5-dimethyl-4-methoxy)pyridylmethylthio]-(5-methoxy)-benzimidazole · HCl (250 g) was mixed with lactose (175.8 g), potato starch (169.7 g) and colloidal silicic acid (32 g). The mixture was moistened with 10% solution of gelatin and was ground through a 12-mesh sieve. After drying, potato
35 starch (160 g), talc (50 g) and magnesium stearate (5 g) were added and the mixture thus obtained was pressed into

tablets (10.000), with each tablet containing 25 mg of active substance. Tablets can be prepared that contain any desired amount of the active ingredient.

5 Example 53. Tablets

Granules were prepared from 2-[2-(3,5-dimethyl-4-methoxy)-pyridylmethylthio]-(5-carbomethoxy-6-methyl)benzimidazole base (250 g), lactose (175.9 g) and an alcoholic
10 solution of polyvinylpyrrolidone (25 g). After drying, the granules were mixed with talc (25 g), potato starch (40 g), and magnesium stearate (2.50 g) and were pressed into 10.000 tablets. These tablets are first coated
15 with a 10% alcoholic solution of shellac and thereupon with an aqueous solution containing saccharose (45%), gum arabic (5%), gelatin (4%), and dyestuff (0.2%). Talc and powdered sugar were used for powdering after the first five coatings. The coating was then covered with a 66% sugar syrup and
20 polished with a solution of 10% carnauba wax in carbon tetrachloride.



Example 54. Solution for injection

2-[2-(3,5-dimethyl-4-methoxy)pyridylmethylthio]-(5-acetyl-6-
25 -methyl)benzimidazole hydrochloride (1 g), sodium chloride (0.6 g) and ascorbic acid (0.1 g) were dissolved in sufficient amount of distilled water to give 100 ml of solution. This solution, which contains 10 mg of active substance for each ml, was used in filling ampoules, which
30 were sterilized by heating at 120°C for 20 minutes.



Biological tests

Gastric acid secretion inhibiting effect on conscious dogs

5 Test Method

Chronic gastric fistula dogs (Heidenhain pouch dogs) were used. These dogs have been surgically provided with a gastric cannula in the pouch. Following a 4 weeks' recovery
10 period after surgery, tests were performed once a week on each dog. Food and water were withdrawn 18 hours before each test.

Gastric acid secretion was induced by continuous infusion
15 of histamine at individual doses (100-300 $\mu\text{mol/kg}$, h), resulting in submaximal secretion of gastric acid. At least 2 hours after onset of stimulation, when the gastric acid secretion had reached a steady level, the test compounds in the form of free base suspended in 0.5% Methocel[®]
20 (90 HG, 15.000, Dow Chem. corp.), were given orally by stomach tube. The gastric juice was collected by free flow from the gastric cannula in consecutive 30 minutes samples for 3 hours. The samples were titrated to pH 7.0 with 0.1 M NaOH using a Radio-meter automatic titrator and
25 the acid output was calculated.


The per cent inhibition of acid secretion was calculated by comparing in each dog the acid output in the tests to the acid output in control tests when only the vehicle was
30 given.

The test results are given in Table 6 below.

Table 6

Gastric acid secretion inhibiting effect on conscious dogs

5 Test compound



Dose
($\mu\text{mol/kg}$) (% inhi-
bition)

10

	R^1	R^2	R	R^3	R^4	R^5		
15	5-OCH ₃	H	H	CH ₃	OCH ₃	CH ₃	2	75
	5-COOCH ₃	H	H	CH ₃	OCH ₃	CH ₃	8	50
	5-COOCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃	2	80
	5-COCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃	2	35
	5-COCH ₃	H	H	CH ₃	OCH ₃	CH ₃	8	90
20	5-CH ₃	H	H	CH ₃	OCH ₃	CH ₃	2	60
	5-COCH ₃	6-CH ₃	H	H	CH ₃	CH ₃	8	80
	5-OCH ₃	H	H	CH ₃	CH ₃	CH ₃	2	75

25


Comment to the test results

It is seen in Table 6 that the tested compounds after oral administration exhibited a high inhibiting effect on the gastric secretion.

30

What we claim is:

1. A pharmaceutical preparation containing as active ingredient a compound of the formula



or a therapeutically acceptable salt thereof, in which formula


R^1 and R^2 are the same or different and each selected from the group consisting of H, CF_3 , NO_2 , $-COOCH_3$, $-COOC_2H_5$, alkyl containing 1-7 carbon atoms, halogen, alkoxy containing 1-5 carbon atoms, and alkanoyl containing 1-4 carbon atoms;

R is selected from the group consisting of H, alkanoyl containing 1-4 carbon atoms, and carboalkoxy containing 2-6 carbon atoms;

and R^3 , R^4 and R^5 , which are the same or different, are each selected from the group consisting of H, CH_3 , C_2H_5 , OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$; provided that

- a) at least one of R^3 , R^4 and R^5 is selected from the group consisting of CH_3 , C_2H_5 , OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$, and
- b) when two of R^3 , R^4 and R^5 are H, then the remaining radical R^3 , R^4 or R^5 is selected from the group consisting of OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$;

optionally in association with a pharmaceutically acceptable carrier.



2. A pharmaceutical preparation according to claim 1,
5 containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each
selected from the group consisting of H, COOCH_3 , COOC_2H_5 ,
alkyl having 1-4 carbon atoms, halogen, alkoxy having 1-3
carbon atoms, and alkanoyl having 1-4 carbon atoms; R is H;
10 and wherein R^3 , R^4 and R^5 are the same or different and
selected from the group consisting of H, CH_3 , C_2H_5 , OCH_3 ,
 OC_2H_5 , $\text{OCH}_2\text{CH}_2\text{OCH}_3$, and $\text{OCH}_2\text{CH}_2\text{OCH}_2\text{CH}_3$.

3. A pharmaceutical preparation according to claim 1,
20 containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each
selected from the group consisting of H, COOCH_3 , CH_3 , Cl,
Br, OCH_3 and CH_3CO ; R is H; and wherein R^3 , R^4 and R^5 are
the same or different and selected from the group consisting
20 of H, CH_3 , OCH_3 , and $\text{OCH}_2\text{CH}_2\text{OCH}_3$.

4. A pharmaceutical preparation according to claim 1,
containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each
25 selected from the group consisting of H, COOCH_3 , CH_3 , OCH_3 ,
and CH_3CO ; R is H; and wherein R^3 , R^4 and R^5 are the same
or different and selected from the group consisting of CH_3
and OCH_3 .

30 5. A pharmaceutical preparation according to claim 1,
containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each
selected from the group consisting of H, COOCH_3 , alkyl
having 1-4 carbon atoms, alkoxy having 1-3 carbon atoms,
35 and alkanoyl having 1-4 carbon atoms; R is H; and wherein
 R^3 , R^4 and R^5 are the same or different and selected from
the group consisting of H, CH_3 , OCH_3 , and OC_2H_5 .

0074341



6. A pharmaceutical preparation according to claim 1,
containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each
selected from the group consisting of H, COOCH_3 , COOC_2H_5 ,
5 alkyl having 1-4 carbon atoms, halogen, alkoxy having 1-3
carbon atoms, and alkanoyl having 1-4 carbon atoms; R is H;
and wherein R^3 is CH_3 ; R^4 is OCH_3 and R^5 is CH_3 .
7. A pharmaceutical preparation according to claim 1,
10 containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each
selected from the group consisting of H, COOCH_3 , COOC_2H_5 ,
alkyl having 1-4 carbon atoms, alkoxy having 1-3
carbon atoms, and alkanoyl having 1-4 carbon atoms; R is H;
15 and wherein R^3 is H, R^4 is OCH_3 and R^5 is CH_3 .
8. A pharmaceutical preparation according to claim 1,
containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each
20 selected from the group consisting of H, COOCH_3 , COOC_2H_5 ,
alkyl having 1-4 carbon atoms, alkoxy having 1-3
carbon atoms, and alkanoyl having 1-4 carbons atoms; R is H;
and wherein R^3 is CH_3 , R^4 is OCH_3 and R^5 is H.
- 25 9. A pharmaceutical preparation according to claim 1,
containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each
selected from the group consisting of H, COOCH_3 , COOC_2H_5 ,
alkyl having 1-4 carbon atoms, alkoxy having 1-3
30 carbon atoms, and alkanoyl having 1-4 carbon atoms; R is H;
and wherein R^3 is H, R^4 is OCH_3 and R^5 is H.
10. A pharmaceutical preparation according to claim 1,
containing as active ingredient a compound of the formula I
35 wherein R^1 and R^2 are the same or different and each
selected from the group consisting of H, COOCH_3 , COOC_2H_5 ,
alkyl having 1-4 carbon atoms, alkoxy having 1-3 carbon
atoms, and alkanoyl having 1-4 carbon atoms; R is H; and
wherein R^3 is CH_3 , R^4 is H and R^5 is CH_3 .



11. A pharmaceutical preparation according to claim 1,
containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each selected
from the group consisting of H, COOCH_3 , COOC_2H_5 , alkyl having
1-4 carbon atoms, alkoxy having 1-3 carbon atoms, and alkanoyl
having 1-4 carbon atoms; R is H, and wherein R^3 is H, R^4 is
 OCH_3 , OC_2H_5 , $\text{OCH}_2\text{CH}_2\text{OCH}_3$ or $\text{OCH}_2\text{CH}_2\text{OCH}_2\text{CH}_3$, and R^5 is H.


12. A pharmaceutical preparation according to claim 1,
containing as active ingredient a compound of the formula I
wherein R^1 and R^2 are the same or different and each selected
from the group consisting of H, COOCH_3 , COOC_2H_5 , alkyl having
1-4 carbon atoms, alkoxy having 1-3 carbon atoms, and alkanoyl
having 1-4 carbon atoms; R is H; and wherein R^3 is CH_3 , R^4 is
 CH_3 , and R^5 is CH_3 .

13. A pharmaceutical preparation according to claim 1,
containing as active ingredient a compound of the formula I
wherein R, R^1 , R^2 , R^3 , R^4 and R^5 are combined as follows:

	R^1	R^2	R	R^3	R^4	R^5
25	5- OCH_3	H	H	CH_3	OCH_3	CH_3
	5- COOCH_3	H	H	CH_3	OCH_3	CH_3
	5- COOCH_3	6- CH_3	H	CH_3	OCH_3	CH_3
	5- COCH_3	6- CH_3	H	CH_3	OCH_3	CH_3
	5- COOH_3	H	H	CH_3	OCH_3	CH_3
30	5- CH_3	H	H	CH_3	OCH_3	CH_3
	5- COCH_3	6- CH_3	H	H	CH_3	CH_3
	5- OCH_3	H	H	CH_3	CH_3	CH_3
	5- COCH_3	6- CH_3	H	H	OCH_3	H
	5- COOCH_3	6- CH_3	H	CH_3	OCH_3	H
35	5- COCH_3	6- CH_3	H	CH_3	CH_3	CH_3
	5- COOCH_3	6- CH_3	H	H	OCH_3	H



14. A pharmaceutical composition according to claim 1, containing as active ingredient a compound of the formula




or a therapeutically acceptable salt thereof.

15. A compound as defined in any of claims 1-14, or a therapeutically acceptable salt thereof, for use in inhibiting gastric acid secretion in mammals and man.

16. A compound as defined in any of claims 1-14, or a therapeutically acceptable salt thereof, for use in the treatment of gastrointestinal inflammatory diseases in mammals and man.

17. A compound of the formula



and therapeutically acceptable salts thereof, in which formula

R^1 and R^2 are the same or different and each selected from the group consisting of H, CF_3 , NO_2 , $-COOCH_3$, $-COOC_2H_5$, alkyl containing 1-7 carbon atoms, halogen, alkoxy containing 1-5 carbon atoms, and alkanoyl containing 1-4 carbon atoms;



R is selected from the group consisting of H; alkanoyl containing 1-4 carbon atoms, and carboalkoxy containing 2-6 carbon atoms;

5 and R^3 , R^4 and R^5 , which are the same or different, are each selected from the group consisting of H, CH_3 , C_2H_5 , OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$; provided that

10 a) at least one of R^3 , R^4 and R^5 is selected from the group consisting of CH_3 , C_2H_5 , OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$, and

15 b) when two of R^3 , R^4 and R^5 are H, then the remaining radical R^3 , R^4 or R^5 is selected from the group consisting of OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$; and provided that

20 c) the radicals R, R^1 , R^2 , R^3 , R^4 and R^5 are selected so that the following compounds are excluded:

R	R^1	R^2	R^3	R^4	R^5
H	5-COCH ₃	6-CH ₃	H	CH ₃	CH ₃
H	4-CH ₃	6-CH ₃	CH ₃	H	CH ₃
25 H	5-COCH ₃	6-CH ₃	CH ₃	CH ₃	CH ₃

18. A compound according to claim 17 or a therapeutically acceptable salt thereof, wherein R is H, R^1 , R^2 , R^3 and R^5 are as defined in claim 17; and wherein R^4 is OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, or $OCH_2CH_2OCH_2CH_3$.


30

19. A compound according to claim 17, and therapeutically acceptable salts thereof, wherein R , R^1 , R^2 , R^3 , R^4 and R^5 are combined as follows:



5	R^1	R^2	R	R^3	R^4	R^5
	5-OCH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-COOCH ₃	H	H	CH ₃	OCH ₃	CH ₃
10	5-COOCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃
	5-COCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃
	5-COCH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-CH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-OCH ₃	H	H	CH ₃	CH ₃	CH ₃
15	5-COCH ₃	6-CH ₃	H	H	OCH ₃	H
	5-COOCH ₃	6-CH ₃	H	CH ₃	OCH ₃	H
	5-COOCH ₃	6-CH ₃	H	H	OCH ₃	H


20. A compound of the formula



or a therapeutically acceptable salt thereof.


21. A process for the preparation of a compound according to any of claims 17-20, by

A. reacting a compound of the formula



II


with a compound of the formula



III


in which formula R, R¹, R², R³, R⁴ and R⁵ are as defined previously and wherein one of Z¹ and Z² is SH and the other of Z¹ and Z² is a leaving group;

B. for the preparation of a compound of the formula I wherein R is H, reacting a compound of the formula



IV

wherein R¹ and R² have the same meaning as given above, with a compound of the formula




wherein R³, R⁴ and R⁵ have the same meaning as given above, to the formation of a compound of the formula I wherein R is H;

C. reacting a compound of the formula




5



VI

wherein R, R¹ and R² have the meaning given above and M is
10 K, Na or Li, with a compound of formula

15




VII

wherein R³, R⁴ and R⁵ have the meaning given above and Z³
is a reactive esterified hydroxy group, to the formation of
20 a compound of the formula I;

D. reduction of a compound of the formula

25




VIII

30


to the formation of a compound of the formula I;

E. for the preparation of a compound of the formula I wherein the radicals R^1 and/or R^2 is COOCH_3 or COOC_2H_5 , reacting a compound of the formula




IX

wherein R , R^3 , R^4 or R^5 are as defined above and wherein Y^1 is $-\text{COOH}$, or a functionally equivalent derivative thereof, and Y^2 is $-\text{COOH}$, or a functionally equivalent derivative thereof, or R^1 , with



X


or



XI


or a functionally equivalent derivative thereof, to the formation of a compound of the formula I wherein R^1 and/or R^2 is CH_3COO or $\text{CH}_3\text{CH}_2\text{COO}$;

F. for the preparation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is OCH_3 , OC_2H_5 , $\text{OCH}_2\text{CH}_2\text{CH}_3$ or $\text{OCH}_2\text{CH}_2\text{OCH}_2\text{CH}_3$, reacting a compound of the formula



XII


wherein R , R^1 and R^2 are as defined above and Z^3 , Z^4 and Z^5 represent either R^3 , R^4 and R^5 respectively, or halogen such as Cl, Br, F or I, or NO_2 , whereby at least one of Z^3 , Z^4 and Z^5 represents halogen or NO_2 , with a compound of the formula



XIII


wherein R^6 is CH_3 , C_2H_5 , $CH_2CH_2OCH_3$ or $CH_2CH_2OCH_2CH_3$, and M is Na, K or Li, to the formation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$;

G. for the preparation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$, reacting a compound of the formula




XIV

wherein R , R^1 and R^2 are as defined above, and Z^6 , Z^7 and Z^8 represent either R^3 , R^4 and R^5 , respectively, or a radical



XV


where Y is halogen, whereby at least one of Z^6 , Z^7 and Z^8 represents OCH_2CH_2Y , with a compound of the formula



XVI

wherein R^7 is CH_3 or CH_2CH_3 and M is Na, K or Li, to the formation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$;


H. for the preparation of a compound of the formula I wherein R is H, hydrolyzing a compound of the formula



XVII

wherein R^1 , R^2 , R^3 , R^4 and R^5 are as defined above and Z^9 is an alkanoyl group or a carboalkoxy group, to the formation of a compound of the formula I wherein R is H;


I. reduction of a compound of the formula



XVIII

to the formation of a compound of the formula I;

J. reduction of a compound of the formula




XIX

whereafter, if desired, the compound thus obtained is converted to a therapeutically acceptable salt.



Claims for Austria

1. A process for the preparation of a compound of the formula



and therapeutically acceptable salts thereof, in which formula


R^1 and R^2 are the same or different and each selected from the group consisting of H, CF_3 , NO_2 , $-COOCH_3$, $-COOC_2H_5$, alkyl containing 1-7 carbon atoms, halogen, alkoxy containing 1-5 carbon atoms, and alkanoyl containing 1-4 carbon atoms;

R is selected from the group consisting of H, alkanoyl containing 1-4 carbon atoms, and carboalkoxy containing 2-6 carbon atoms;

and R^3 , R^4 and R^5 , which are the same or different, are each selected from the group consisting of H, CH_3 , C_2H_5 , OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$; provided that

a) at least one of R^3 , R^4 and R^5 is selected from the group consisting of CH_3 , C_2H_5 , OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$, and

b) when two of R^3 , R^4 and R^5 are H, then the remaining radical R^3 , R^4 or R^5 is selected from the group consisting of OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$, and $OCH_2CH_2OCH_2CH_3$; and provided that




c) the radicals R , R^1 , R^2 , R^3 , R^4 and R^5 are selected so that the following compounds are excluded:

R	R^1	R^2	R^3	R^4	R^5
H	5-COCH ₃	6-CH ₃	H	CH ₃	CH ₃
H	4-CH ₃	6-CH ₃	CH ₃	H	CH ₃
H	5-COCH ₃	6-CH ₃	CH ₃	CH ₃	CH ₃


by

A. reacting a compound of the formula



II

with a compound of the formula





III

in which formula R , R^1 , R^2 , R^3 , R^4 and R^5 are as defined previously and wherein one of Z^1 and Z^2 is SH and the other of Z^1 and Z^2 is a leaving group;


B. for the preparation of a compound of the formula I wherein R is H, reacting a compound of the formula

4.6




IV

wherein R^1 and R^2 have the same meaning as given above, with a compound of the formula




15 wherein R^3 , R^4 and R^5 have the same meaning as given above, to the formation of a compound of the formula I wherein R is H;

C. reacting a compound of the formula



VI

25 wherein R, R^1 and R^2 have the meaning given above and M is K, Na or Li, with a compound of formula




VII

35 wherein R^3 , R^4 and R^5 have the meaning given above and Z^3 is a reactive esterified hydroxy group, to the formation of a compound of the formula I;

D. reduction of a compound of the formula




VIII




to the formation of a compound of the formula I;

E. for the preparation of a compound of the formula I wherein the radicals R^1 and/or R^2 is COOCH_3 or COOC_2H_5 , reacting a compound of the formula




IX

wherein R , R^3 , R^4 or R^5 are as defined above and wherein Y^1 is $-\text{COOH}$, or a functionally equivalent derivative thereof, and Y^2 is $-\text{COOH}$, or a functionally equivalent derivative thereof, or R^1 , with



X


or



XI


or a functionally equivalent derivative thereof, to the formation of a compound of the formula I wherein R^1 and/or R^2 is CH_3COO or $\text{CH}_3\text{CH}_2\text{COO}$;

F. for the preparation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is OCH_3 , OC_2H_5 , $OCH_2CH_2CH_3$ or $OCH_2CH_2OCH_2CH_3$, reacting a compound of the formula



XII


wherein R , R^1 and R^2 are as defined above and Z^3 , Z^4 and Z^5 represent either R^3 , R^4 and R^5 respectively, or halogen such as Cl, Br, F or I, or NO_2 , whereby at least one of Z^3 , Z^4 and Z^5 represents halogen or NO_2 , with a compound of the formula



XIII


wherein R^6 is CH_3 , C_2H_5 , $CH_2CH_2OCH_3$ or $CH_2CH_2OCH_2CH_3$, and M is Na, K or Li, to the formation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$;

G. for the preparation of a compound of the formula I wherein at least one of R^3 , R^4 and R^5 is $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$, reacting a compound of the formula




XIV

wherein R, R¹ and R² are as defined above, and Z⁶, Z⁷ and Z⁸ represent either R³, R⁴ and R⁵, respectively, or a radical



XV


where Y is halogen, whereby at least one of Z⁶, Z⁷ and Z⁸ represents OCH₂CH₂Y, with a compound of the formula



XVI

wherein R⁷ is CH₃ or CH₂CH₃ and M is Na, K or Li, to the formation of a compound of the formula I wherein at least one of R³, R⁴ and R⁵ is OCH₂CH₂OCH₃ or OCH₂CH₂OCH₂CH₃;


H. for the preparation of a compound of the formula I wherein R is H, hydrolyzing a compound of the formula



XVII

wherein R¹, R², R³, R⁴ and R⁵ are as defined above and Z⁹ is an alkanoyl group or a carboalkoxy group, to the formation of a compound of the formula I wherein R is H;


I. reduction of a compound of the formula



XVIII

to the formation of a compound of the formula I;

J. reduction of a compound of the formula




XIX

to the formation of a compound of the formula I;

whereafter, if desired, the compound of the formula I thus obtained is converted to a therapeutically acceptable salt.


2. A process according to claim 1 for the preparation of a compound as defined in claim 1, or a therapeutically acceptable salt thereof, wherein R is H; R^1 , R^2 , R^3 and R^5 are as defined in claim 1; and wherein R^4 is OCH_3 , OC_2H_5 , $OCH_2CH_2OCH_3$ or $OCH_2CH_2OCH_2CH_3$.

3. A process according to claim 1 for the preparation of a compound as defined in claim 1, or a therapeutically acceptable salt thereof, wherein R, R^1 , R^2 , R^3 , R^4 and R^5 are combined as follows:



	R ¹	R ²	R	R ³	R ⁴	R ⁵
5	5-OCH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-COOCH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-COOCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃
	5-COCH ₃	6-CH ₃	H	CH ₃	OCH ₃	CH ₃
	5-COCH ₃	H	H	CH ₃	OCH ₃	CH ₃
10	5-CH ₃	H	H	CH ₃	OCH ₃	CH ₃
	5-OCH ₃	H	H	CH ₃	CH ₃	CH ₃
	5-COCH ₃	6-CH ₃	H	H	OCH ₃	H
	5-COOCH ₃	6-CH ₃	H	CH ₃	OCH ₃	H
	5-COOCH ₃	6-CH ₃	H	H	OCH ₃	H

15 A process according to claim 1 for the preparation of the compound of the formula



25 or a therapeutically acceptable salt thereof.



European Patent
Office

EUROPEAN SEARCH REPORT

0074341

Application number

EP 82 85 0166

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
D, X	--- EP-A-0 005 129 (HÄSSLE) *Page 2,3,5 to 7,9 to 11,13,14; examples 31,33-34; claims 15,16*	17-21	C 07 D 401/12 A 61 K 31/415 A 61 K 31/44
A	--- FR-A-2 392 021 (HÄSSLE) *Pages 1,4 to 6,11 to 13; exam- ples 31,33-37,39-41*& US - A - 4 045 563 & NL - A - 7 513 141 & CH - A - 623 582 & AT - B - 351 524 & AT - B - 337 697 & BE - A - 834 973 & SE - A - 416 649	17-21	
A	--- FR-A-2 261 007 (HÄSSLE) -----		
			TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
			C 07 D 401/00 A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 18-11-1982	Examiner DE BUYSER I.A.F.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



ANHANG ZUM INTERNATIONALEN RECHERCHENBERICHT ÜBER DIE INTERNATIONALE PATENTANMELDUNG NR.

EP 9201341
SA 60325

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentdokumente angegeben.
Die Angaben über die Familienmitglieder entsprechen dem Stand der Datei des Europäischen Patentamts am 01/09/92
Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

In Recherchenbericht angeführtes Patentdokument	Datum der Veröffentlichung	Mitglied(er) der Patentfamilie	Datum der Veröffentlichung
EP-A- 0342522	23-11-89	JP-A- 1290628	22-11-89
		DE-U- 6890056	30-01-92
		US-A- 5035899	30-07-91
EP-A- 0247983	02-12-87	GB-A- 2189698	04-11-87
		AU-B- 601974	27-09-90
		AU-A- 7191287	05-11-87
		CA-A- 1292693	03-12-91
		EP-A- 0496437	29-07-92
		JP-A- 62258320	10-11-87
		US-A- 4786505	22-11-88
EP-A- 0244380	04-11-87	GB-A- 2189699	04-11-87
		AU-B- 603568	22-11-90
		AU-A- 7192287	05-11-87
		JP-A- 62258316	10-11-87
		SU-A- 1709894	30-01-92
		US-A- 4853230	01-08-89

EPO FORM PWT3